title: Bisphosphonate therapy for secondary osteoporosis: adult perspective.
abstract: BACKGROUND
  A number of disease states and drugs can upset the balance between bone formation and resorption resulting in increased fracture risk. Glucocorticoids are the most recognized cause of secondary osteoporosis. Hypogonadism, weight loss, and chronic inflammation are other contributors to bone loss in a variety of disease states. Bisphosphonates are potent inhibitors of bone resorption, and there is a variety of secondary osteoporosis where they produce substantial increases in bone density and reduce fracture risk by about 50%. Upper gastrointestinal tract intolerance with oral agents and a flu-like syndrome with intravenous bisphosphonates are the principal adverse effects associated with their use.
  
  
  CONCLUSIONS
  Numerous disease states and medications can adversely affect the skeleton. Additional effects of aging and menopause can substantially increase an individual's fracture risk. It is important that physicians assess fracture risk in susceptible patients and initiate treatment when indicated.
authors.affiliation: Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. i.reid@auckland.ac.nz
authors.forename: Ian R
authors.initials: IR
authors.lastname: Reid
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids